Micofenolato De Mofetilo Accord

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Accord, is an immunosuppressant (antimetabolite) presented as a pharmaceutical product for oral and intravenous use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis in adult patients.

GNH USA supplies Micofenolato De Mofetilo Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Mycophenolate Mofetil is used in immunosuppressive therapy for solid‑organ transplantation and selected autoimmune disorders.

- Organ transplant rejection: Reduces the risk of acute rejection episodes in kidney, heart, liver and other solid‑organ transplants. - Lupus nephritis: Helps control renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Autoimmune disease management: Provides disease‑modifying effects in certain vasculitic and connective‑tissue disorders when prescribed by a specialist.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Hematologic changes: leukopenia, anemia, or thrombocytopenia. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Headache or dizziness.

Serious or Rare Side Effects: - Severe infections such as opportunistic pneumonia or sepsis. - Progressive multifocal leukoencephalopathy (PML). - Hepatotoxicity: elevated liver enzymes or hepatic failure. - Malignancies: increased risk of post‑transplant lymphoproliferative disorder. - Pregnancy‑related complications: fetal loss or birth defects.

Before initiating therapy, clinicians should assess baseline laboratory values and monitor patients regularly.

- Monitor blood counts: perform complete blood count weekly for the first month, then monthly. - Assess renal function: check serum creatinine and eGFR before and during treatment. - Screen for infections: evaluate for latent viral infections (e.g., CMV, EBV) and treat appropriately. - Avoid live vaccines: patients on therapy should not receive live attenuated vaccines. - Pregnancy warning: discontinue if pregnancy is confirmed; discuss contraception with women of childbearing potential. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Mycophenolate Mofetil interacts with several drugs that affect its absorption or metabolism.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce mycophenolate absorption; separate dosing by at least 2 hours. - Azathioprine: additive bone‑marrow suppression; avoid concurrent use. - Live viral vaccines: increased risk of severe infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics): may increase mycophenolic acid levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may decrease drug exposure. - Vaccines: non‑live vaccines are generally safe but monitor immune response.